How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?

Pediatric Blood and Cancer

Volumn 61, Issue 1, 2014, Pages 7-10

  Cohen, Ian Joseph ^a,b   Wolff, Johannes E ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Dose; Folinic acid; Leucovorin rescue; Methotrexate; Timing

Indexed keywords

FOLINIC ACID; METHOTREXATE; DIHYDROFOLATE REDUCTASE; ANTINEOPLASTIC AGENT; VITAMIN B COMPLEX;

ATAXIA; CALCIFICATION; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; NEUROTOXICITY; OPTIMAL DRUG DOSE; PARESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEIZURE; SOMNOLENCE; SYSTEMATIC REVIEW; THERAPY DELAY; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW SUPPRESSION; EVENT FREE SURVIVAL; MUCOSA INFLAMMATION; SURVIVAL TIME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANTINEOPLASTIC AGENTS; HUMANS; LEUCOVORIN; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VITAMIN B COMPLEX;

EID: 84891675185     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24770     Document Type: Review

References (41)

1. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948;238:787-793.
2. Levitt M, Mosher MB, DeConti RC, et al. Improved therapeutic index of methotrexate with "leucovorin rescue". Cancer Res 1973;33:1729-1734.
3. Mahoney DH, Jr., Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose methotrexate with intravenous mercaptopurine for children with lower-risk B lineage acute lymphoblastic leukemia: A Pediatric Oncology Group phase III trial. J Clin Oncol 1998;16:246-254.
4. Lasen EC, Saizer WL, Davidas M, et al. Comparison of high dose methotrexate (HDM-TX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study (AALL0232). J Clin Oncol 2011;29:6s.
5. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
6. Cohen IJ. Defining the appropriate dose of folinic acid after high dose methotrexate for acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Ped Hematol Oncol 2004;26:156-163.
7. Borsi JD, Sagen E, Romslo I, et al. Pharmacokinetics and metabolism of methotrexate: An example for the use of clinical pharmacology in pediatric oncology. Pediatr Hematol Oncol 1990;7:13-33.
8. Bertino JR. "Rescue" techniques in cancer chemotherapy: Use of leucovorin and other rescue agents after methotrexate treatment. Semin Oncol 1977;4:203-215.
9. Bleyer WA. The clinical pharmacology of methotrexate: New applications of an old drug. Cancer 1978;41:36-51.
10. Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern. Eur J Cancer 1972;8:409-414.
11. BleyerWA. Methotrexate: Clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977;4:87-101.
12. Djerassi I, Kim JS. Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas): Prolonged unmaintained remissions. Cancer 1976;38:1043-1051.
13. Selawry OS, Hansen HH. Induction of increased tolerance to methotrexate in man. Proceedings of the Tenth International Cancer Congress, 1970, p. 452.
14. Bertino JK, Donohue DM, Simmons B, et al. The "induction" of dihydrofolic reductase activity in leukocytes and erythrocytes of patients treated with amethopterin. J Clin Invest 1963;42:466- 475.
15. Jurgens H, Janka G, Ibrahim M, et al. Prognostic significance of exposure to intermediate-dose methotrexate in children with standard risk ALL: The COALL 82/85 experience. Haematol Blood Transfus 1992;34:338-342.
16. Frickel C,Wolfrom C, Belz S, et al. Pharmacokinetics of MTX and rescue folates in HD MTX treatment with low leucovorin rescue. Med Pediatr Oncol 1993;21:568-568.
17. Amparo-Buendia MT, Lozano JM, Suarez GE, et al. The impact of lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia. J Pediatr Hematol Oncol 2008;30:643-650.
18. Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate dose versus 4 hour high dose infusion for remission induction in relapsed childhood acute lymphatic leukemia. J Clin Oncol 1993;11:827-833.
19. Camitta B, Mahoney D, Leventhal B, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 1994;12:1383-1389.
20. Mahoney DH Jr, Shuster JJ, Nitschke SR. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-A Pediatric Oncology Group study. J Clin Oncol 1998;16:1712-1722.
21. Bell B, Abish S, Shuster J, et al. Neurotoxicity (NT) in patients with standard-risk acute lymphatic leukemia (ALL) on Pediatric Oncology Group (POG) 9405. Blood 1997;90:559A.
22. Von Stackelberg A, Yamanak J, Escherich G, et al. Conventional Reinduction/consolidation type therapy versus short course high intensity combination chemotherapy as post induction treatment for children with relapsed acute lymphoblastic leukemia. Early results of study BFM ALL-REZ 2002. Blood 2011;118:397-397.
23. Joannon P, Oviedo I, Campell M, et al. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: Lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 2004;43:17-22.
24. Winik NJ, Bowman WP, Kamen BA, et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992;84:252-256.
25. Wang JJ, Freeman AI, Sinks LF. Treatment of acute lymphatic leukemia by high-dose intravenous methotrexate. Cancer Res 1976;36:1441-1444.
26. Mikkelsen TS, Sparreboom A, Cheng C, et al. Shortening infusion time for high-dose methotrexate alters antileukemic effects: A randomized prospective clinical trial. J Clin Oncol 2011;29:1771-1778.
27. Reddick WE, Glass JO, Helton KJ, et al. Prevalence of leukoencephalopathy in children treated for acute lymphatic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 2005;26:1263-1269.
28. Rubnitz JE, Relling MV, Harrison PL, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998;12:1176-1181.
29. Vezmar S, Schüsseler P, Becker A, et al. Methotrexate-associated alterations of the folate and methyltransfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer 2009;52:26-32.
30. Montour-Proulx I, Kuehn SM, Keene DL, et al., Cognitive changes in children treated for acute lymphoblastic leukemia with chemotherapy only according to the Pediatric Oncology Group 9605 protocol. J Child Neurol 2005;20:129-133.
31. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood 2005;105:948-958.
32. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
33. Brugie'res L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL Group. J Clin Oncol 2009;27:897-903.
34. Salzer WL, Jones TL, Devidas M, et al. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. Pediatr Blood Cancer 2012;59:834-839.
35. Wolff JEA, Gnekow AK, Kortmann R, et al. Preradiation chemotherapy for pediatric patients with highgrade glioma. Cancer 2002;94:264-271.
36. Camitta B, Holcenberg JS. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children. Med Pediatr Oncol 1978;5:55-59.
37. Balis FM, Savitch JL, Bleyer WA, et al. Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 1985;3:485-489.
38. Cohen IJ. High-dose methotrexate is effective in osteosarcoma so what is the problem? J Pediatr Hematol Oncol 2009;12:892-894.
39. Bonda-Shkedi E, Arush MW, Kaplinsky C, et al. The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): A neuropsychological and psychosocial study. Pediatr Hematol Oncol 2013;35:271-275.
40. Kamen BA,Weitman SD. High-dose methotrexate: Is it warranted? Pediatr Hematol Oncol 1994;11:135- 137.
41. Seidel H, Moe PJ, Nygaard R, et al. Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr Hematol Oncol 1994;11:165-172.